CN105963567A - 治疗糖尿病的药物及制备方法 - Google Patents
治疗糖尿病的药物及制备方法 Download PDFInfo
- Publication number
- CN105963567A CN105963567A CN201610511752.3A CN201610511752A CN105963567A CN 105963567 A CN105963567 A CN 105963567A CN 201610511752 A CN201610511752 A CN 201610511752A CN 105963567 A CN105963567 A CN 105963567A
- Authority
- CN
- China
- Prior art keywords
- supernatant
- filtrate
- polysaccharide
- volume
- boiling water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title description 11
- 150000004676 glycans Chemical class 0.000 claims abstract description 87
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 58
- 239000005017 polysaccharide Substances 0.000 claims abstract description 58
- 244000302512 Momordica charantia Species 0.000 claims abstract description 25
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 25
- 240000008042 Zea mays Species 0.000 claims abstract description 23
- 230000009471 action Effects 0.000 claims abstract description 4
- 239000006228 supernatant Substances 0.000 claims description 46
- 239000000706 filtrate Substances 0.000 claims description 45
- 238000009835 boiling Methods 0.000 claims description 27
- 238000003809 water extraction Methods 0.000 claims description 26
- 235000007244 Zea mays Nutrition 0.000 claims description 21
- 229940089639 cornsilk Drugs 0.000 claims description 21
- 239000001231 zea mays silk Substances 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 18
- 230000033228 biological regulation Effects 0.000 claims description 17
- 238000000108 ultra-filtration Methods 0.000 claims description 8
- 102000057297 Pepsin A Human genes 0.000 claims description 7
- 108090000284 Pepsin A Proteins 0.000 claims description 7
- 229940111202 pepsin Drugs 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 108090000145 Bacillolysin Proteins 0.000 claims description 5
- 102000035092 Neutral proteases Human genes 0.000 claims description 5
- 108091005507 Neutral proteases Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 210000001835 viscera Anatomy 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 9
- 239000002994 raw material Substances 0.000 abstract description 5
- 230000003907 kidney function Effects 0.000 abstract description 4
- 241000237502 Ostreidae Species 0.000 abstract description 3
- 235000020636 oyster Nutrition 0.000 abstract description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 2
- 235000005822 corn Nutrition 0.000 abstract 2
- 230000001603 reducing effect Effects 0.000 abstract 2
- 230000000857 drug effect Effects 0.000 abstract 1
- 150000004804 polysaccharides Polymers 0.000 description 29
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 201000001421 hyperglycemia Diseases 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 10
- 230000002218 hypoglycaemic effect Effects 0.000 description 9
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229960003624 creatine Drugs 0.000 description 4
- 239000006046 creatine Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000010977 jade Substances 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960004329 metformin hydrochloride Drugs 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 241000548230 Crassostrea angulata Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明一种原料来源广泛、成本低廉、可有效提高降糖效果且无副作用的治疗糖尿病的药物及制备方法,是以牡蛎多糖、玉米须多糖及苦瓜多糖按质量比为5~6:2~3:2~3组合而成。降血糖的效果及综合药效显著好于牡蛎多糖、玉米须多糖或者苦瓜多糖单独作用效果,同时本发明还可对糖尿病患者的肾功能起到了明显地改善作用。
Description
技术领域
本发明涉及一种治疗糖尿病的药物及制备方法,尤其是一种原料来源广泛、成本低廉、可有效提高降糖效果且无副作用的治疗糖尿病的药物及制备方法。
背景技术
糖尿病是以高血糖为特征的一系列代谢紊乱的疾病,长期存在的高血糖可导致各种组织(眼、肾、心脏、血管、神经等)的慢性损害、功能障碍,目前对于糖尿病的治疗大多采用磺脲类、双胍类等降糖药物。磺脲类、双胍类等药物在降糖的同时会对人体产生副作用,最常见表现为恶心、呕吐、食欲下降、腹痛、腹泻;头痛、头晕、金属味;乳酸酸中毒,伴有肝、肾功能减退等,因此药物应用禁忌症较多,如严重肝、肾、心、肺疾病,消耗性疾病,营养不良,缺氧性疾病,妊娠期等均禁止使用。
牡蛎是我国重要的养殖贝类,也是全世界分布最广的贝类。人们对于牡蛎的药用价值早有认识。《本草纲目》中记载牡蛎肉具有治疗虚损、调中、解丹毒、妇人血气的作用。以姜、醋生食,治丹毒,酒后烦热,止渴。牡蛎多糖是牡蛎中重要的活性物质,对于它的研究已有很多报道。Shi等以太平洋牡蛎为原料,采用热水萃取方法得到水溶性牡蛎多糖,研究了牡蛎多糖对四氯化碳诱导的急性肝损伤以及酒精诱导的慢性肝损伤的保护作用,结果表明灌胃牡蛎多糖的小鼠血清中谷草转氨酶(AST)、谷丙转氨酶(ALT)活性以及丙二醛(MDA)含量降低,超氧化物歧化酶(SOD)活性升高,说明牡蛎多糖对肝脏具有较强的保护作用(Shi等发表于2015年第78卷第142-148页的《International Journal of BiologicalMacromolecules》上)。贾淑杰等研究了玉米须乙醇及水提取物对小鼠的降血糖作用,发现两种提取物对高血糖和肾上腺素所致的小鼠高血糖有降低作用(贾淑杰等发表于2012年第8期第40卷第809-811页的《天津医药》上)。苦瓜果实含有丰富的皂苷、黄酮、多肽、多糖等多种生物活性物质,具有降血糖、抗癌、抗病毒等作用。但是,迄今为止,还没有将牡蛎多糖、玉米须多糖及苦瓜多糖进行组合进行降糖的研究报道。
发明内容
本发明是为了解决现有技术所存在的上述技术问题,提供一种原料来源广泛、成本低廉、可有效提高降糖效果且无副作用的治疗糖尿病的药物及制备方法。
本发明的技术解决方案是:一种治疗糖尿病的药物,其特征在于是以牡蛎多糖、玉米须多糖及苦瓜多糖按质量比为5~6:2~3:2~3组合而成。
一种上述治疗糖尿病的药物的制备方法,所述的牡蛎多糖按如下方法制备:将牡蛎去壳及去内脏之后进行匀浆处理,用体积/质量为15倍的沸水浸提10min,过滤得滤液;对滤渣用体积/质量为15倍的沸水浸提10min,过滤得滤液;合并滤渣再用体积/质量为15倍的沸水浸提10min,过滤得滤液;将3次滤液合并调节pH为5~6,过夜放置,6000rpm离心20min,收集上清;上清液调节pH为1.5~2.5,向上清液加入胃蛋白酶,在温度为37℃条件下进行保温酶解4h,再次6000rpm离心20min,胃蛋白酶的加入量为上清液质量1%×6000活性单位/克;获得的酶解上清液经过截留分子量10kDa的超滤膜过滤,再将过膜截留的滤液进行喷雾干燥,得到牡蛎多糖。
所述玉米须多糖按如下方法制备:将玉米须粉碎,用体积/质量为15倍的沸水浸提10min,过滤得滤液;对滤渣用体积/质量为15倍的沸水浸提10min,过滤得滤液;合并滤渣再用体积/质量为15倍的沸水浸提10min,过滤得滤液;将3次滤液合并调节pH为4~5,过夜放置,6000rpm离心20min,收集上清;上清液调节pH为1.5~2.5,向上清液加入胃蛋白酶,在温度为37℃条件下进行保温酶解4h,再次6000rpm离心20min,胃蛋白酶的加入量为上清液质量1%×6000活性单位/克;获得的酶解上清液经过截留分子量10kDa的超滤膜过滤,再将过膜截留的滤液进行喷雾干燥,得到玉米须多糖。
所述苦瓜多糖按如下方法制备:新鲜苦瓜去籽去瓤,进行匀浆处理,用体积/质量为10倍的沸水浸提10min,过滤得滤液;对滤渣用体积/质量为10倍的沸水浸提10min,过滤得滤液;合并滤渣再用体积/质量为10倍的沸水浸提10min,过滤得滤液;将3次滤液合并调节pH为5~6,过夜放置,6000rpm离心20 min,收集上清;上清液调节pH为6.5~7.5,向上清液加入中性蛋白酶,在温度为37℃条件下进行保温酶解4h,再次6000rpm离心20min,中性蛋白酶的加入量为上清液质量1%×6000活性单位/克;获得的酶解上清液经过截留分子量10kDa的超滤膜过滤,再将过膜截留的滤液进行喷雾干燥,得到苦瓜多糖。
本发明原料来源广泛、成本低廉、可有效提高降糖效果且无副作用,降血糖的效果及综合药效显著好于牡蛎多糖、玉米须多糖或者苦瓜多糖单独作用效果,同时本发明还可对糖尿病患者的肾功能起到了明显地改善作用。
具体实施方式
实施例1:
以牡蛎多糖、玉米须多糖及苦瓜多糖按质量比为6:2:2混合而成,可制成片剂、散剂、颗粒剂、口服液或注射液等各种剂型。
所述的牡蛎多糖按如下方法制备:将牡蛎去壳及去内脏之后进行匀浆处理,用体积/质量为15倍的沸水浸提10min,过滤得滤液;对滤渣用体积/质量为15倍的沸水浸提10min,过滤得滤液;合并滤渣再用体积/质量为15倍的沸水浸提10min,过滤得滤液;每次浸提过程中均需间歇搅拌,将3次滤液合并调节pH为6,过夜放置,6000rpm离心20min,收集上清;上清液调节pH为2,向上清液加入胃蛋白酶,在温度为37℃条件下进行保温酶解4h,再次6000rpm离心20min,胃蛋白酶的加入量为上清液质量1%×6000活性单位/克,即若上清液为1000克,则加入60000活性单位的胃蛋白酶;若上清液为800克,则加入48000活性单位的胃蛋白酶。在温度为37℃条件下进行保温酶解4h,再次6000rpm离心20min;获得的酶解上清液经过截留分子量10kDa的超滤膜过滤,再将过膜截留的滤液进行喷雾干燥,得到牡蛎多糖,牡蛎多糖纯度≥90%。
所述玉米须多糖按如下方法制备:将玉米须粉碎,用体积/质量为15倍的沸水浸提10min,过滤得滤液;对滤渣用体积/质量为15倍的沸水浸提10min,过滤得滤液;合并滤渣再用体积/质量为15倍的沸水浸提10min,过滤得滤液;每次浸提过程中均需间歇搅拌,将3次滤液合并调节pH为4,过夜放置,6000rpm离心20min,收集上清;上清液调节pH为2,向上清液加入胃蛋白酶,在温度为37℃条件下进行保温酶解4h,再次6000rpm离心20min,胃蛋白酶的加入量为上清液质量1%×6000活性单位/克;获得的酶解上清液经过截留分子量10kDa的超滤膜过滤,再将过膜截留的滤液进行喷雾干燥,得到玉米须多糖,玉米须多糖纯度≥90%。
所述苦瓜多糖按如下方法制备:新鲜苦瓜去籽去瓤,进行匀浆处理,用体积/质量为10倍的沸水浸提10min,过滤得滤液;对滤渣用体积/质量为10倍的沸水浸提10min,过滤得滤液;合并滤渣再用体积/质量为10倍的沸水浸提10min,过滤得滤液;每次浸提过程中均需间歇搅拌,将3次滤液合并调节pH为5,过夜放置,6000rpm离心20 min,收集上清;上清液调节pH为7,向上清液加入中性蛋白酶,在温度为37℃条件下进行保温酶解4h,再次6000rpm离心20min,中性蛋白酶的加入量为上清液质量1%×6000活性单位/克;获得的酶解上清液经过截留分子量10kDa的超滤膜过滤,再将过膜截留的滤液进行喷雾干燥,得到苦瓜多糖,苦瓜多糖纯度≥90%。
实施例2:
以牡蛎多糖、玉米须多糖及苦瓜多糖按质量比为5:3:2混合而成,可制成片剂、散剂、颗粒剂、口服液或注射液等各种剂型。
制备方法同实施例1。
实施例3:
以牡蛎多糖、玉米须多糖及苦瓜多糖按质量比为6:2:3混合而成,可制成片剂、散剂、颗粒剂、口服液或注射液等各种剂型。
制备方法同实施例1。
实验:
实验材料:
四氧嘧啶、乙酸铵购于Sigma公司。盐酸二甲双胍购于北京京丰制药集团。尿肌酐测定试剂盒、尿素氮测定试剂盒、糖化血清蛋白测定试剂盒、胆固醇测定试剂盒、甘油三酯测定试剂盒购于南京建成生物工程研究所。
实验仪器:
三诺安稳血糖仪(三诺生物传感股份有限公司);HH-2型数显恒温水浴锅(国华电器有限公司);UV-1750紫外分光光度计(苏州岛津仪器有限公司);IEC MicroCL 17R微量台式小型高速离心机(德国Thermo公司);电子天平(北京赛多利斯仪器系统有限公司)。
实验分组及用药:
SPF级ICR雄性小鼠,体质量18~22 g,购自大连医科大学实验动物中心。取SPF级ICR雄性小鼠180只,适应性饲养3 d,随机挑选10只作为正常对照组,其余动物禁食15 h(不禁水),由尾静脉快速注射新鲜配制的四氧嘧啶生理盐水溶液(80mg/kg),建立糖尿病动物模型(血糖值≥11.1 mmol/L的小鼠,且连续出现多饮、多食、多尿、体质量减轻症状者为糖尿病小鼠)。正常对照组注射等体积的生理盐水,96 h后(禁食12 h)尾静脉取血测定小鼠空腹血糖水平。
将成模的动物按体质量和血糖水平随机分高血糖组、盐酸二甲双胍组和给药组(200、400、800 mg/kg/day)12个剂量组。盐酸二甲双胍组给予200mg/kg/day盐酸二甲双胍,给药组(本发明实施例1、牡蛎多糖组、玉米须多糖组以及苦瓜多糖组)按不同剂量灌胃给药。给药组每天给药2次,正常对照组、高血糖组每天灌胃蒸馏水2次,间隔6 h,连续21d。第7、14、21d测小鼠空腹血糖,测试前禁食12 h。第7d测小鼠体重、饮水量、饮食量。
生化指标检测:
第21d收集尿液,用检测试剂盒测定尿肌酐、尿素氮。
第21d测定空腹血糖后,摘眼球取血,分离血清,果糖胺法测定其中糖化血清蛋白含量(GSP),酶偶联比色法测定甘油三酯(TG)、总胆固醇(TC)含量。
实验结果:
一.对四氧嘧啶致ICR小鼠糖尿病模型降血糖的影响如表1。
表1 牡蛎多糖对四氧嘧啶致ICR小鼠糖尿病模型降血糖的影响
注:(1)同一行数据中上标字母不同代表存在显著差异(P <0.05);
(2)与高血糖组相比,*代表差异显著(P <0.05);**代表差异极显著(P <0.01)
表1结果表明:给药7 d与给药0 d相比,盐酸二甲双胍组(200 mg/kg/day)、本发明实施例1组(200、400、800 mg/kg/day)、牡蛎多糖组(400、800 mg/kg/day)、玉米须多糖组(200、400、800 mg/kg/day)和苦瓜多糖组(400、800 mg/kg/day)的空腹血糖值下降显著(P <0.05),牡蛎多糖组(200 mg/kg/day)、苦瓜多糖组(200 mg/kg/day)的空腹血糖值下降不显著(P >0.05)。与高血糖组相比,盐酸二甲双胍组(200 mg/kg/day)、本发明实施例1组(200、400 mg/kg/day)、牡蛎多糖组(400、800 mg/kg/day)、玉米须多糖组(200、400、800 mg/kg/day)和苦瓜多糖组(800 mg/kg/day)的空腹血糖值下降极显著(P <0.01),本发明实施例1组(800 mg/kg/day)和牡蛎多糖组(200 mg/kg/day)的空腹血糖值下降显著(P <0.05)。与给药7d相比,给药14d、21d的盐酸二甲双胍组(200 mg/kg/day)、本发明实施例1组(200、400、800 mg/kg/day)、牡蛎多糖组(200、400、800 mg/kg/day)、玉米须多糖组(200、400、800mg/kg/day)和苦瓜多糖组(200、400、800 mg/kg/day)的空腹血糖值变化不显著(P >0.05),表明给药后血糖值维持稳定。
二.对四氧嘧啶致ICR小鼠糖尿病TG、TC、GSP的影响见表2。
表2 对四氧嘧啶致ICR小鼠糖尿病TG、TC、GSP的影响
注:(1)与正常组相比,*代表差异显著(P <0.05);**代表差异极显著(P <0.01)
(2)与高血糖组相比,#代表差异显著(P <0.05);##代表差异极显著(P <0.01)
表2结果表明,与高血糖组相比,盐酸二甲双胍组(200 mg/kg/day)、本发明实施例1组(200、400、800 mg/kg/day)、牡蛎多糖组(200、400 mg/kg/day)和玉米须多糖组(200、400mg/kg/day)的TG含量均显著下降(P <0.05);盐酸二甲双胍组(200 mg/kg/day)、发明实施例1组(200 mg/kg/day)、牡蛎多糖组(200 mg/kg/day)、玉米须多糖组(400 mg/kg/day)和苦瓜多糖组(200 mg/kg/day) TC含量显著下降(P <0.05),发明实施例1组(400 mg/kg/day)、牡蛎多糖组(400 mg/kg/day)和玉米须多糖组(200 mg/kg/day) TC含量下降极显著(P <0.01);盐酸二甲双胍组(200 mg/kg/day)、发明实施例1组(200、400、800 mg/kg/day)、牡蛎多糖组(200、400、800 mg/kg/day)和玉米须多糖组(200、400、800 mg/kg/day)、苦瓜多糖组(200 mg/kg/day)的GSP含量下降极显著(P <0.01),苦瓜多糖组(400、800 mg/kg/day)的GSP含量下降显著(P <0.05)。
三.对四氧嘧啶致ICR小鼠糖尿病的综合药效评价
按照综合药效评价公式进行评价:
综合药效评价(%)=体质量增加率(%)×0.2+饮水降低率(%)×0.15+摄食降低率(%)×0.15+血糖降低率(%)×0.5
实验结果如表3:
表3 对糖尿病小鼠的综合药效评价
表3结果表明:给药后小鼠表现出体重增加,饮水量和摄食量下降。本发明实施例1组(200、400、800 mg/kg/day)的综合药效评价高于牡蛎多糖组(200、400、800 mg/kg/day)、玉米须多糖组(200、400、800 mg/kg/day)、苦瓜多糖组(200、400、800 mg/kg/day),并且本发明实施例1(800 mg/kg/day)的综合药效评价值最高。
四.各组小鼠尿肌酐和尿素氮水平
表4 各组小鼠尿肌酐和尿素氮水平
注:(1)与正常组相比,*代表差异显著(P <0.05);**代表差异极显著(P <0.01)
(2)与模型组相比,#代表差异显著(P <0.05);##代表差异极显著(P <0.01)
表4结果表明:与高血糖组相比,本发明实施例1组(400、800 mg/kg/day)及牡蛎多糖组(400、800 mg/kg/day)的尿素氮和尿肌酐下降极显著(P <0.01),本发明实施例1组(200mg/kg/day)和牡蛎多糖组(200 mg/kg/day)组的尿素氮和尿肌酐下降显著(P <0.05)。本发明实施例1组肾功能指标参数显著降低。
结论:将本发明的药物对四氧嘧啶导致的糖尿病ICR小鼠的降血糖作用实验,结果显示本发明的药物对四氧嘧啶导致的糖尿病ICR小鼠的降血糖及综合药效显著好于牡蛎多糖、玉米须多糖或者苦瓜多糖单独作用,表现出显著的增效作用,同时本发明的药物明显改善ICR小鼠的肾功能。
Claims (4)
1.一种治疗糖尿病的药物,其特征在于是以牡蛎多糖、玉米须多糖及苦瓜多糖按质量比为5~6:2~3:2~3组合而成。
2.一种如权利要求1所述治疗糖尿病的药物的制备方法,其特征在于所述的牡蛎多糖按如下方法制备:将牡蛎去壳及去内脏之后进行匀浆处理,用体积/质量为15倍的沸水浸提10min,过滤得滤液;对滤渣用体积/质量为15倍的沸水浸提10min,过滤得滤液;合并滤渣再用体积/质量为15倍的沸水浸提10min,过滤得滤液;将3次滤液合并调节pH为5~6,过夜放置,6000rpm离心20min,收集上清;上清液调节pH为1.5~2.5,向上清液加入胃蛋白酶,在温度为37℃条件下进行保温酶解4h,再次6000rpm离心20min,胃蛋白酶的加入量为上清液质量1%×6000活性单位/克;获得的酶解上清液经过截留分子量10kDa的超滤膜过滤,再将过膜截留的滤液进行喷雾干燥,得到牡蛎多糖。
3.根据权利要求2所述治疗糖尿病的药物的制备方法,其特征在于所述玉米须多糖按如下方法制备:将玉米须粉碎,用体积/质量为15倍的沸水浸提10min,过滤得滤液;对滤渣用体积/质量为15倍的沸水浸提10min,过滤得滤液;合并滤渣再用体积/质量为15倍的沸水浸提10min,过滤得滤液;将3次滤液合并调节pH为4~5,过夜放置,6000rpm离心20min,收集上清;上清液调节pH为1.5~2.5,向上清液加入胃蛋白酶,在温度为37℃条件下进行保温酶解4h,再次6000rpm离心20min,胃蛋白酶的加入量为上清液质量1%×6000活性单位/克;获得的酶解上清液经过截留分子量10kDa的超滤膜过滤,再将过膜截留的滤液进行喷雾干燥,得到玉米须多糖。
4.根据权利要求3所述治疗糖尿病的药物的制备方法,其特征在于所述苦瓜多糖按如下方法制备:新鲜苦瓜去籽去瓤,进行匀浆处理,用体积/质量为10倍的沸水浸提10min,过滤得滤液;对滤渣用体积/质量为10倍的沸水浸提10min,过滤得滤液;合并滤渣再用体积/质量为10倍的沸水浸提10min,过滤得滤液;将3次滤液合并调节pH为5~6,过夜放置,6000rpm离心20min,收集上清;上清液调节pH为6.5~7.5,向上清液加入中性蛋白酶,在温度为37℃条件下进行保温酶解4h,再次6000rpm离心20min,中性蛋白酶的加入量为上清液质量1%×6000活性单位/克;获得的酶解上清液经过截留分子量10kDa的超滤膜过滤,再将过膜截留的滤液进行喷雾干燥,得到苦瓜多糖。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610511752.3A CN105963567B (zh) | 2016-07-01 | 2016-07-01 | 治疗糖尿病的药物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610511752.3A CN105963567B (zh) | 2016-07-01 | 2016-07-01 | 治疗糖尿病的药物及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105963567A true CN105963567A (zh) | 2016-09-28 |
CN105963567B CN105963567B (zh) | 2019-08-30 |
Family
ID=56954362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610511752.3A Active CN105963567B (zh) | 2016-07-01 | 2016-07-01 | 治疗糖尿病的药物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105963567B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111450136A (zh) * | 2020-06-12 | 2020-07-28 | 广西医科大学 | 一种牡蛎葛根复合颗粒及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1872134A (zh) * | 2006-04-21 | 2006-12-06 | 江苏大学 | 一种苦瓜多糖降血糖组合物及其制备方法 |
CN102702582A (zh) * | 2011-11-07 | 2012-10-03 | 赛珂睿德生物医药科技(上海)有限公司 | 玉米须多糖及其制备方法和用途 |
CN104861083A (zh) * | 2015-06-14 | 2015-08-26 | 威海紫光金奥力生物技术有限公司 | 一种海洋牡蛎生物多糖提取制备方法 |
-
2016
- 2016-07-01 CN CN201610511752.3A patent/CN105963567B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1872134A (zh) * | 2006-04-21 | 2006-12-06 | 江苏大学 | 一种苦瓜多糖降血糖组合物及其制备方法 |
CN102702582A (zh) * | 2011-11-07 | 2012-10-03 | 赛珂睿德生物医药科技(上海)有限公司 | 玉米须多糖及其制备方法和用途 |
CN104861083A (zh) * | 2015-06-14 | 2015-08-26 | 威海紫光金奥力生物技术有限公司 | 一种海洋牡蛎生物多糖提取制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111450136A (zh) * | 2020-06-12 | 2020-07-28 | 广西医科大学 | 一种牡蛎葛根复合颗粒及其制备方法 |
CN111450136B (zh) * | 2020-06-12 | 2021-12-14 | 广西医科大学 | 一种牡蛎葛根复合颗粒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105963567B (zh) | 2019-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101277710B (zh) | 减肥组成物 | |
CN104432084B (zh) | 一种调理粉及其制备方法和用途 | |
CN103445117B (zh) | 一种能够预防酒精性肝损伤的葛根保健营养粉 | |
CN102526479B (zh) | 一种增强免疫力、降血糖功能的保健药物 | |
CN106360310A (zh) | 一种降低餐后血糖的组合物及其应用 | |
CN102526478B (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
CN102524667A (zh) | 具有治疗糖尿病的挂面及其制备方法 | |
CN105265985B (zh) | 一种玉米须固体饮料及其制备方法 | |
CN105030984B (zh) | 一种具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液及制备方法 | |
WO2007007993A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea l. var. edulis extract | |
CN106176953A (zh) | 一种包含青钱柳叶、罗汉果和桑叶的降血糖保健组合物 | |
CN106177183A (zh) | 一种包含青钱柳叶、绿茶和桑叶的降血糖保健组合物 | |
CN103653148A (zh) | 一种番石榴叶液体饮料 | |
CN108403818A (zh) | 一种辅助降血糖的组合物及其用途 | |
CN107137420A (zh) | 一种具有清热养阴降血糖功能的桑叶菊花山药复合多糖及其制备方法 | |
CN103920140B (zh) | 一种人用降糖减肥降脂复方制剂 | |
CN101336965B (zh) | 一种用于改善糖耐量、降低血糖的中成药及其制备方法 | |
CN103719997B (zh) | 一种番石榴固体饮料 | |
CN105963567B (zh) | 治疗糖尿病的药物及制备方法 | |
CN1297353A (zh) | 降血糖剂 | |
CN114009795A (zh) | 一种保护肝脏的大鲵肽营养组合物 | |
CN102198174B (zh) | 滋肾清肝降糖调脂中药配方制剂及其制备方法 | |
CN104687051A (zh) | 一种海洋生物营养液及其制备方法 | |
CN104352748A (zh) | 一种治疗糖尿病肾病的中药组合物及其制备方法 | |
CN103445215B (zh) | 一种能够预防酒精性肝损伤的禽蛋干 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |